| Title |
Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX
|
| Creator |
Harvey N. C.
Kanis J. A.
Oden A.
Nakamura T.
Shiraki M.
Kuroda T.
Johansson H.
McCloskey E. V.
|
| Source Title |
OSTEOPOROSIS INTERNATIONAL
|
| Volume | 26 |
| Issue | 9 |
| Start Page | 2347 |
| End Page | 2353 |
| Journal Identifire |
ISSN 0937-941X
EISSN 1433-2965
|
| Subjects | |
| Language |
eng
|
| Resource Type | journal article |
| Publisher |
SPRINGER LONDON LTD
|
| Date of Issued | 2015-09 |
| Access Rights | metadata only access |
| Relation |
[DOI] 10.1007/s00198-015-3129-7
[PMID] 26092062
|
| Remark | NH has received consultancy, lecture fees, and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, Consilient Healthcare, and Internis Pharma. JA Kanis has received consulting fees, advisory board fees, lecture fees, and/or grant support from the majority of companies concerned with skeletal metabolism. EVM has received consultancy, lecture fees, research grant support, and/or honoraria from ActiveSignal, Alliance for Better Bone Health, AMGEN, Bayer, Consilient Healthcare, GE Lunar, Hologic, Internis Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Servier, Tethys, UCB, and Univadis. TN received research grants and/or consulting fees from Chugai Pharmaceutical, Teijin Pharma, Asahi Kasei Pharma, and Daiichi Sankyo. MS received consulting fees from Chugai, Daiichi Sankyo, Asahi Kasei Pharma, Teijin Pharma, and MSD. TS received consulting fee and/or research grant from Asahi-Kasei Pharma, Daiichi-Sankyo-Co., Eli Lilly Japan, and Pfizer. TK is an employee of Asahi Kasei Pharma Corporation. Anders Oden and Helena Johansson declare that they have no conflict of interest. |
